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Antibodies that bind residue K169 in the V2 region of
the HIV-1 envelope correlated with reduced risk of
infection in the RV144 vaccine trial but were
restricted to two ED-motif-encoding light chain
genes. Here, we identify an HIV-infected donor with
high-titer V2 peptide-binding antibodies and isolate
two antibody lineages (CAP228-16H/19F and
CAP228-3D) that mediate potent antibody-depen-
dent cell-mediated cytotoxicity (ADCC). Both line-
ages use the IGHV5-51 heavy chain germline gene,
similar to the RV144 antibody CH58, but one lineage
(CAP228-16H/19F) uses a light chain without the ED
motif. A cocrystal structure of CAP228-16H bound
to a V2 peptide identified a IGLV3-21 gene-encoded
DDxD motif that is used to bind K169, with a mecha-
nism that allows CAP228-16H to recognize more
globally relevant V2 immunotypes. Overall, these
data further our understanding of the development
of cross-reactive, V2-binding, antiviral antibodies
and effectively expand the human light chain reper-
toire able to respond to RV144-like immunogens.
INTRODUCTION
TheRV144vaccine trialwas thefirstHIV-1phase III humanclinical
trial to showa favorable outcome,withamoderate31.2%efficacyCell Repo
This is an open access article under the CC BY-N(Rerks-Ngarm et al., 2009). A case-control analysis showed that
cross-reactive binding antibodies specific for the V2 region of
HIV-1 Env correlated inversely with infection risk (Haynes et al.,
2012). Selection pressure was identified at positions 169 and
181 in V2, and vaccine efficacywas greater (48%) when viruses
had a matched V2 K169 residue (Rolland et al., 2012). The V2 re-
gion of Env is also a target for broadly neutralizing antibodies
(bNAbs), and position 169 is often a mutational hot spot for anti-
body escape during infection (Moore et al., 2011; Wibmer et al.,
2013, 2015). However, since vaccine-induced V2 antibodies
were only able to neutralize sensitive tier 1 virus strains, exactly
how these antibodies contributed to reduced infection rates re-
mains unknown (Rerks-Ngarm et al., 2009).
The isolation of several monoclonal antibodies (mAbs) from
RV144 vaccinees that bound short, linear, V2 peptide epitopes
spanningpositions 166–182ofEnv, haveprovidedpossiblemech-
anisms of action. These V2 mAbs were able to mediate antibody-
dependent cell-mediated cytotoxicity (ADCC) against CD4+ target
cells coated in Env derived from breakthrough infections (Liao
et al., 2013) and subtype AE HIV-1 CM235 infectious molecular
clone-infected target cells (Pollara et al., 2014). Among RV144
vaccinees, 28% had V2 plasma antibody levels sufficient to
mediate ADCC and tier 1 neutralization (Rerks-Ngarm et al.,
2009). Furthermore, the binding footprints of the isolated V2
mAbs overlap with a tripeptide motif in V2 (position 179–181)
that binds the adhesion receptor a4b7 (Arthos et al., 2008).
Antibodies that block this interaction have been shown to reduce
simian immunodeficiency virus (SIV) acquisition and impact path-
ogenesis in the non-human primatemodel (Byrareddy et al., 2014,
2016).rts 25, 3123–3135, December 11, 2018 ª 2018 The Authors. 3123
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Structural studies of two RV144 mAbs, CH58 and CH59,
showed that the V2 peptide epitope can be structurally dynamic,
as both mAbs bound to different conformations of V2 (Liao et al.,
2013). CH58 recognizes region 167–176 as an a-helix, and
177–181 as coiled loop, while CH59 binds region 168–173 as a
coil, and 174–176 as a short 310-helix. This differs from bNAbs,
which only bind conformational epitopes that include region
167–181 as one of five b-strands forming part of a ‘‘Greek key
motif’’ in prefusion Env trimers (Gorman et al., 2016; Julien et al.,
2013;McLellan et al., 2011; Pancera et al., 2014). Non-neutralizing
V2 antibodies previously isolated from HIV-1-infected donors
(such as 830A) also bind to this five-stranded b-barrel conforma-
tion of V2, but their epitopes are not exposed on native, pre-fusion
trimers (Pan et al., 2015). Similarly, the peptide epitopes recog-
nizedbyvaccineantibodiesCH58andCH59are likelyonlypresent
on aberrantly processed or refolded forms of V2, which coexist
with native pre-fusion Env on the viral membrane (Moore et al.,
2006). These aberrant forms of Env are the primary target for
non-neutralizingantibodiesmediating Fceffector functions,which
may have contributed toward the reduced infection risk in RV144.
In the case of RV144 V2 antibodies, these antiviral activities
were largely dependent on the interactions with positively
charged residues at positions 168, 169, and 171 in V2. In both
CH58 and CH59, this binding was mediated predominantly by
a glutamic-aspartic amino acid pair (ED motif) in the antibody
CDRL2 (Liao et al., 2013; Wiehe et al., 2014), which is structurally
preconfigured in the naive B cell to interact with V2 (Nicely et al.,
2015). Recognition of V2 by other RV144 mAbs, as well as mAbs
from vaccinated non-human primates, also required the same ED
motif, although alternative solutions could potentially be found
among other animal models that lack an appropriate ED-motif-
encoding genome (Wiehe et al., 2014, 2017). In humans the ED
motif is encoded by only two functionally expressed light chain
germline genes, IGLV3-10 and IGLV6-57 (Lefranc, 2001). This
suggests a limited capacity for eliciting these types of potentially
protective antibodies, even though the V2 region is highly immu-
nogenic, and 20%–45% of HIV-1-infected individuals develop
V2-specific antibodies (Israel et al., 1997; Kayman et al., 1994).
Therefore, to assess whether other modes of K169 binding ex-
isted, we screenedHIV-positive plasma samples for K169-depen-
dent, V2 peptide-binding antibodies, and isolated threemAbs that
resembled the RV144 vaccine antibody CH58. All mAbs used the
same IGHV5-51 heavy chain, but two mAbs used a light chain
that lacked an ED motif. A crystal structure of one of these,
CAP228-16H, bound to a V2 peptide revealed how a surrogate
DDxDmotif enabledbinding toK169. The identification of this third
light chain gene capable of binding V2 broadens the K169-binding
repertoire that can respond to RV144 vaccine antigens. Overall,
these data contribute toward a better understanding of K169-
focused V2 epitopes and the antibodies that target them, which
are considered essential for RV144 vaccine efficacy.
RESULTS
Isolation of V2 Peptide-Binding Antibodies from HIV-1
Infection
To identify HIV-infected individuals with RV144-like antibodies,
we screened plasma samples from 15 HIV-1 subtype C chroni-3124 Cell Reports 25, 3123–3135, December 11, 2018cally infected donors for binding to V2 peptides and V1V2 scaf-
folded proteins (Figure 1A). Hierarchical clustering of reactivity
was used to divide the plasmas into three groups: V2 peptide-
binding antibodies (clustering with CH58/CH59), monomeric
V1V2-binding antibodies (clustering with PG9) (Walker et al.,
2009), and antibodies with limited-to-no monomer reactivity
(clustering with CH01) (Bonsignori et al., 2011). One-half of the
selected participants developed bNAbs during infection,
including two to the V2 region (CAP256 and CAP257) (Gray
et al., 2011a; Moore et al., 2011; Wibmer et al., 2013), but we
saw no obvious binding patterns to these antigens among those
individuals with bNAbs. Almost all plasma samples contained
cross-reactive V1V2 antibodies, with binding to the Case
A_gp70 protein used in the RV144 correlates analysis being
the strongest. However, only two participants (CAP228 and
CAP229) developed high-titer, cross-reactive, V2 peptide-bind-
ing antibodies similar to CH58 and CH59 from RV144.
Longitudinal analysis revealed that donor CAP228 devel-
oped V2 peptide-binding antibodies within 7 weeks of infection
that peaked at 36 weeks and remained high thereafter (Fig-
ure 1B). A large proportion of this response was dependent
on the K169 residue, as binding to a K169E mutant peptide
was considerably reduced. CAP228 did not develop neutrali-
zation breadth during this time and maintained relatively low
viral loads for 6 years before initiating antiretroviral therapy.
To find representative mAbs, memory B cells from CAP228
were isolated at 134 and 174 weeks post-infection (wpi) using
a differential K169/E169 single-cell sorting strategy (Figure 1C).
A total of 416 cells were sorted, yielding three K169-dependent
mAbs that bound strongly to V2 peptides in ELISA (Figure 1D).
The mAb CAP228-3D was isolated at 134 wpi only, while a
related pair of mAbs, CAP228-16H/19F, were isolated at
both 134 and 174 wpi. When compared with RV144-elicited
antibodies, the CAP228 antibodies were relatively less affected
by the K169E substitution, with only a 10-fold reduction in EC50
compared to CH58 where binding was knocked out. CH59
failed to bind the CAP45 V2 peptides (not shown). All three
CAP228 mAbs shared a common IGHV5-51 heavy chain
gene also used by CH58 (Figure 1E, highlighted in blue).
CAP228-3D also used the same IGLV6-57 gene as CH58,
while CAP228-16H and CAP228-19F (which are clonally
related) used a IGLV3-21 light chain gene (Figure 1E, high-
lighted yellow and purple). This latter gene does not encode
the characteristic K169-binding CDRL2 ED motif but does
have potentially analogous negatively charged residues at
the same positions (Figure 1E, bolded in red). The CAP228-
3D antibody had a 19-amino acid-long CDRH3 (as defined
by the ImMunoGeneTics database), like CH58, while the
CDRH3s of CAP228-16H/19F were slightly shorter (16 amino
acids), although still relatively longer than the average
CDRH3 lengths observed for CH59-like antibodies (Wiehe
et al., 2014). All three CAP228 antibodies had moderately
higher levels of mutation as expected for antibodies from
infection when compared to those after immunization. Most
noticeably, mutation levels of the two IGLV3-21 light chains
(antibodies CAP228-16H/19F) were higher than that of the
matched heavy chains, suggesting these may have been under
stronger selection pressure.
Figure 1. Isolation of V2p-Binding Anti-
bodies from an HIV-1-Infected Donor
(A) Hierarchical clustering of 15 HIV-1+ plasma
samples and four anti-V2 mAbs (labeled on the
right) based on their relative reactivity with V2
peptides or scaffolded V1V2 antigens (labeled on
the top and in the key) in an ELISA. Plasma sam-
ples and mAbs with broadly neutralizing activity
are indicatedwith an asterisk on the left-hand side.
Binding intensity was recorded as a relative per-
centage of maximum OD, where 0%–40% was
colored yellow; 40%–80%, orange; and 80%–
100%, red. Samples were grouped either with
mAbsCH58 andCH59 (based on strong binding to
peptides), with PG9 (based on binding to mono-
meric V1V2 proteins), or with CH01 (based on
no/limited binding to the peptides or proteins).
(B) ELISA binding of CAP228 longitudinal plasma
to CAP45 wild-type (blue) and K169E mutant
(cyan) cyclical V2 peptides. Absorbance readings
are plotted on the y axis against time on the x axis.
The 134 and 174 wpi time points at which mAbs
were isolated from stored PBMC samples are
indicated with the vertical dotted lines.
(C) Fluorescence-activated cell sorting (FACS) plot
showing the CAP228 memory B cells (in blue) that
bind BV421-labeled wild-type (y axis), but not
AF647-labeled K169E mutant (x axis) V2 peptide
antigens, and were therefore sorted for PCR
amplification.
(D) ELISA titers (y axis) of three CAP228 mAbs
(16H, 19F, and 3D) to both wild-type and K169E
mutant V2 peptides from CAP45 (colored as in B),
when compared to the RV144 vaccine antibody
CH58 (CH59 did not bind to CAP45 V2 peptides).
4E10 is an HIV-1 gp41 peptide-reactive mAb used
as a negative control (Buchacher et al., 1994).
(E) Properties of the CAP228 antibodies, defined
by the International Immunogenetics Database
(IMGT), compared to vaccine-elicited mAbs CH58
and CH59. CDRH3 lengths are also given for
Kabat numbering in parentheses. Shared immu-
noglobulin germline genes are shaded, and the
negatively charged amino acids in each CDRL2
are shown in red.The K169-Dependent V2-Binding Repertoire Is Not
Limited to ED-Motif Germline Genes
To trace the ontogeny of the CAP228 antibody lineages, gene-
specific antibody transcripts were sequenced from peripheral
blood mononuclear cells (PBMCs) at seven time points using
the Illumina MiSeq platform. Identity-divergence plots revealed
clonally related heavy and light chains as early as 7 wpi (Figures
S1A and S1B; Table S1), consistent with ELISA mapping data
showing the rapid elicitation of V2-binding antibodies (refer to
Figure 1B). Despite this rapid emergence, the CAP228 V2 anti-
bodies were not autoreactive and were thus unlikely to have
arisen from a preexisting polyreactive B cell pool (Table S2).
Although CAP228-16H was isolated at 134 wpi, exact matches
to the heavy chain of this antibody were detected at 96, 134,and 174 wpi, while CAP228-16H/19F lineage-related reads
were detected at all time points sequenced (Figures S1A, S2A,
and S2B). In contrast, while CAP228-3D clonally related light
chains were found at all time points sampled, related heavy
chains were only detected above threshold at 47 wpi (Figures
S1B, S3A, and S3B). CAP228-3D uses the same heavy chain
V gene as CAP228-16H/19F and was thus amplified using the
same IGHV5-51-specific primers, suggesting a sampling bias
that might represent increased clonal expansion of this family
when compared to the CAP228-3D lineage.Maximum-likelihood
phylogenetic trees for the heavy and light chains of the
CAP228-16H/19F lineage (and the light chains of the CAP228-
3D lineage) were drawn using the isolated antibody sequences
and clonally related MiSeq reads to estimate lineage evolutionCell Reports 25, 3123–3135, December 11, 2018 3125
(Figures 2A and S1C). The CAP228-16H/19F unmutated precur-
sor (or UCA) was identified directly from these data using the
least mutated common ancestor (LMCA) of clonally related
heavy and light chain sequences from 7 wpi, while the
CAP228-3D precursor was calculated by germline reversion of
the heavy chain, matched with the LMCA light chain from related
reads at 7wpi.
The predicted CAP228-16H/19F light chain UCA shared the
highest similarity with the IGLV3-21*01 allele, which encodes a
tyrosine-aspartic acid pair (YD) at position 49–50 in the CDRL2
rather than the two aspartic acids (DD) observed in the
CAP228-16H/19F lineage (Figure 2B, highlighted yellow and
blue). However, the CAP228-16H UCA also shared a synony-
mous allelic similarity with the DD-encoding IGLV3-21*02/03
alleles at position 92 (Figure 2B, highlighted red). To confirm
the origin of the CAP228-16H/19F lineage, the germline
IGLV3-21 alleles of CAP228 were amplified from genomic
DNA and sequenced. This revealed two previously undocu-
mented IGLV3-21 alleles, IGLV3-21*01m and IGLV3-
21*01mm (using a similar nomenclature for novel alleles as
previously reported in Scheepers et al., 2015), where IGLV3-
21*01m had a single synonymous mutation at position 92
(also found in IGLV3-21*02/03) when compared to IGLV3-
21*01. IGLV3-21*01mm further differed from IGLV3-21*01m
by also including the non-synonymous change from Y to
D at position 50 (Figure 2B, bottom row). Both the IGLV3-
21*01m and IGLV3-21*01mm predicted UCA variants were
synthesized and tested for their ability to bind the trans-
mitted/founder autologous CAP228 V1V2 in ELISA. Only the
DD-encoding UCA (IGLV3-21*01mm) bound the antigen (Fig-
ure 2C, blue and yellow lines). Together with longitudinal
lineage sequencing, these data suggested that the IGLV3-
21*01mm allele with the CDRL2-encoded DD pair initiated
the CAP228-16H/19F lineage.
Since the IGLV3-21*01mm allele has not been previously
described, we also assessed the known IGLV3-21*02/03 DD-
encoding alleles for their ability to engage V2 antigens. Both
the I48V mutation (that reverted the CAP228-16H/19F UCA to
IGLV3-21*03) as well as the K17Q mutation (converting the
CAP228-16H/19F UCA to IGLV3-21*02) bound equally well to
V1V2 (Figure 2C, pink and purple lines), confirming the relevance
of both common IGLV3-21 allelic variants in the V2-targeted im-
mune response. An analysis of allelic frequencies using ExaC
(Lek et al., 2016) suggested that the average prevalence of
DD-encoding IGLV3-21 alleles in the general population is 60%
(Figure 2D). The only population group to show significant varia-
tion from this was East Asia, where the frequency was much
lower at 26%, perhaps explaining why this light chain was not
represented among RV144 mAbs. Overall, the identification of
this additional light chain broadens the pool of potential
K169-dependent V2-reactive human B cells able to respond to
RV144 antigens.
The IGLV3-21 CDRL2 DDxD Motif Interacts with
V2 Residues K168, K169, and Y173
As CAP228-16H/19F lacked the CDRL2 ED motif used by
vaccine-elicited mAbs to interact with positively charged res-
idues at positions K168 and K169/K171, we hypothesized that3126 Cell Reports 25, 3123–3135, December 11, 2018the negatively charged DD residues in the IGLV3-21 CDRL2
could make similar contacts with V2. To investigate this, a
cocrystal structure of CAP228-16H bound to the heterologous
CAP45 V2 peptide (residues 164–182) was determined at
2.6 A˚ resolution (Figure 3; Table 1). CAP228-16H bound to
V2 in a conformation that was highly similar to CH58 (Liao
et al., 2013), with the N-terminal half of the peptide adopting
an a-helical conformation, and the C-terminal portion, a
random coil structure (Figure 3A). Electrostatic analysis of
the CAP228-16H light chain paratope revealed a large anionic
patch, created by three aspartic acid residues in the CDRL2 at
positions 50, 51, and 53 (Figure 3B, highlighted in red). This
formed a DDxD motif that was analogous to the ED motif of
CH58 (positions 50 and 51), but covering a relatively larger
surface area.
An aspartic acid at position D51 was common to both anti-
bodies and was similarly oriented to interact with K168 in V2
(Figure 3C, boxed in pale blue). In contrast, the D50 side chain
of CAP228-16H is one carbon shorter than the E50 residue of
CH58, potentially weakening any interactions with K169.
Instead, K169 forms a surrogate water-mediated interaction
with the IGLV3-21 germline encoded D53 residue, broadening
the K168-K169 recognition motif to include an additional nega-
tively charged side chain (Figure 3C, boxed in pale red). The
space vacated by K169 is instead occupied by the CAP45
Y173 residue, which forms a hydrogen bond with D50 that is
not seen in the interaction between CH58 and the TH023 V2
peptide, containing the H173 immunotype (Figure 3C, boxed
in pale green). To assess the effectiveness of the IGLV3-21
CDRL2 as a surrogate for the IGLV3-10 or IGLV6-57 encoded
ED motif, position 50 of the CAP228-16H light chain was
mutated to glutamic acid (E) and assessed for binding to the
transmitted/founder autologous CAP228 V1V2 in ELISA. The
ED version of CAP228-16H bound equally well to V2 when
compared with the original DDxD version, with only a twofold
difference in EC50 (Figure 3D). Altogether, these data confirm
the suitability of the DDxD motif to serve as a surrogate for
the ED motif, by forming a larger anionic patch that recognizes
V2 residues K168 and K169, and also forms interactions with
position Y173.
The tyrosines at V2 residues 173 and 177 are also potentially
subject to tyrosine sulfation, which is thought to stabilize prefu-
sion trimers through CCR5 mimicry (Cimbro et al., 2014, 2016).
Intriguingly, while the V2 peptide used here for structural study
was not synthesized with sulfated tyrosines, we observed
additional density around position Y177, which we attributed
to a sulfate ion that facilitated cocrystallization of the
CAP228-16H/V2 complex by also forming important crystal lat-
tice contacts. This sulfate ion was likely from the mother liquor
during crystallization but was fortuitously oriented to occupy
the same space as a sulfated tyrosine would on virion-associ-
ated V1V2 (Figure 3E). An arginine at position 97 in the
CAP228-16H CDRH3 interacts directly with the Y177-associ-
ated sulfate ion, suggesting that during HIV-1 infection the
CAP228-16H lineage could have evolved to recognize a post-
translationally sulfated Y177 residue. This ability to bind
sulfated tyrosines potentially increases the functional activity
of the CAP228 antibodies.
Figure 2. Identification of the CAP228-16H/19F UCA and Lambda IGLV3-21 Germline Alleles
(A) Maximum-likelihood phylogenetic trees of unique, clonally related sequences, for the heavy (left) and light (right) chain of the CAP228-16H/19F lineage, with
branches colored by time point. Mature CAP228-16H and 19F mAb sequences are colored according to the time point at which they were first observed rather
than when they were isolated. Trees were rooted to the least mutated common ancestor (LMCA).
(B) Alignment of the two additional CAP228 IGLV3-21 germline alleles, when compared to the IMGT sequences for IGLV3-21*01, IGLV3-21*02, and IGLV3-21*03.
Shared synonymous (positions 9 or 92) and non-synonymous (positions 17, 48, or 50) differences are indicated with alternate shading, where the key YD/DD
amino acid pair is colored yellow or blue, respectively.
(C) ELISA binding of the CAP228-16H/19F UCA to an autologous transmitted/founder CAP228 V1V2 scaffolded protein. Absorbance readings are plotted on the
y axis versus mAb concentration on the x axis. Binding of the CAP228-16H/19F UCA allelic variants for IGLV3-21*02 (pink) and IGLV3-21*03 (purple) are also
shown. IGLV3-21*01 shares the same amino acid sequence as IGLV3-21*01m.
(D) Frequency of the DD (blue) or YD (yellow) motifs among global allelic variants of the IGVL3-21 germline genes (data from The 1000 Genomes Project [Auton
et al., 2015]).
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Figure 3. Atomic-Level Details of the
Interaction between CAP228-16H and V2
Residues
(A) Cartoon representation of the CAP228-16H
Fab domain bound to V2 peptide residues 164–
182 from viral strain CAP45 (colored white). Heavy
and light chains are colored green and purple,
respectively, and the variable or constant domains
of the Fab are labeled.
(B) Surface representation of the CAP228-16H
paratope (top), compared to the CH58 paratope
(bottom), with the bound V2 peptide depicted as a
helix-loop cartoon with side chains shown in stick
representation. The Fab heavy chains are colored
green and blue, respectively, while the light chains
are colored per electrostatic potential. The CH58
CDRH3 was colored with partial transparency to
show the underlying V2 peptide. The large elec-
tronegative patch encoded by the IGLV3-21 DDxD
motif, or the IGLV6-57 ED motif, is indicated, and
K168 in V2 is labeled for perspective.
(C) A zoom-in of the atomic detail interactions
(shown with side chain sticks) between V2 resi-
dues K168, K169, and Y/H173, and the CAP228-
16H light chain DDxD or CH58 ED motifs.
Hydrogen bonds are indicated with the dotted
lines, andwatermolecules are shownwith the blue
spheres. The antibody CDRL2 and CDRH3 loops,
as well as the interacting amino acid pairs being
compared, are labeled.
(D) ELISA showing binding to the autologous
transmitted/founder CAP228 V1V2 scaffolded
protein by wild-type CAP228-16H (green), and the
ED-motif mutant (red), when compared to anti-
bodies that naturally contain the ED motif:
CAP228-3D (purple), CH58 (blue), and CH59
(gray). Absorbance readings are plotted on the
y axis versus mAb concentration on the x axis.
(E) 2Fo-Fc density map of V2 residue Y177,
showing the associated sulfate ion, oriented by
CAP228-16H CDRH3 residue R97.CAP228 Antibodies Mediate ADCC against Globally
Prevalent V2 Immunotypes
To compare the epitope of CAP228-16H with the vaccine-
elicited antibody CH58, the percentage of accessible surface
area for each V2 amino acid side chain that was buried within
the respective antibody paratopes was compared in the two
crystal structures (Figure 4A). The overall binding profile was
strikingly similar, with K168, A/V172, Y/H173, L175, F176,
K/R178, and D180 burying more than 50% of their accessible
surface area in the antibody paratope and forming major
components of the antibody binding sites. These positions are
among the most conserved in V2 across globally circulating
strains in the Los Alamos National Laboratory HIV-1 Env data-
base and are likely important determinants of the cross-reactivity3128 Cell Reports 25, 3123–3135, December 11, 2018for V2-binding antibodies (Figure 4B).
Several key differences between the
two antibodies were also apparent (Fig-
ure 4A, highlighted in yellow). Unlike
CH58, CAP228-16H did not make strongsalt bridges with K169 and K171, both of which are relatively
more sequence-variable residues across different strains of
HIV-1. CAP228-16H and CH58 both sequester the amino acid
side chain at position 173 almost in its entirety but make specific
hydrogen bonds with the Y173 or H173 immunotypes, respec-
tively. The Y173 immunotype recognized by CAP228-16H is
present in the majority (65%) of HIV-1 circulating strains (Fig-
ure 4B, boxed in yellow), with a higher proportion of H173 found
among clade AE viruses (55%when compared to 19% globally),
which includes the RV144 vaccine strain. Together with a
reduced dependence on sequence-variable residues at posi-
tions 169 and 171, and the ability to recognize Y177 sulfation,
these data suggest that CAP228-like antibodies might better
recognize more globally dominant V2 immunotypes.
Table 1. X-Ray Crystallographic Data and Refinement Statistics
(Molecular Replacement) for the Antigen-Binding Fragment of
CAP228-16H in Complex with HIV-1 CAP45 V2 Peptide
CAP228-16H Bound to
CAP45 V2 Peptide
Data Collection
Space group P212121
Cell dimensions
a, b, c (A˚) 40.29, 104.27, 212.22
a, b, g () 90, 90, 90
Resolution (A˚) 35.37–2.58 (2.67–2.58)a
Unique reflections 26,374 (1,710)
Rmerge 0.158 (0.373)
a
Rpim 0.068 (0.263)
a
I / sI 10.4 (2.1)a
CC1/2 0.951 (0.873)a
Completeness (%) 90.2 (59.4)a
Redundancy 5.1 (2.5)a
Refinement
Resolution (A˚) 50–2.58
No. reflections 26,364 (1,709)
Rwork/Rfree 0.22/0.25
No. atoms (no H) 6.922
Protein 6,786
Other 20
Solvent 116
B factors (no H) 72
Protein 72
Other 87
Solvent 53
Wilson B-factor (A˚2), all atoms 54
RMS deviations
Bond lengths (A˚) 0.003
Bond angles () 0.650
Ramachandran favored % 96.5%
Ramachandran outliers % 0.0%
Rotamer outliers % 0.1%
Molprobity clash score 1.5
MolProbity overall score 1.0
PDB ID 6FY0
aValues in parentheses are for highest-resolution shells.To assess whether these recognition differences might impact
on the antiviral activities of V2-binding antibodies, the ability
of the CAP228 mAbs to mediate both neutralization and ADCC
was tested. Similar to CH58 and CH59, the CAP228 antibodies
were able to neutralize some tier 1A viruses in a TZM-bl neutral-
ization assay (Figure 4C), but they displayed marginally more
activity than CH58 and were able to neutralize both the subtype
AE TH023 (neutralized by CH58 and CH59) and the subtype
C MW965 strains (the latter with good potency; highlighted in
red on the heatmap). However, none of the other tier 1A viruses,including those from subtype C, was sensitive to any of the
CAP228mAbs. For themost part, tier 1A neutralization sensitivity
trackedwell with the presence of a lysine at position 169 (with the
exception of SO032). These mAbs also failed to neutralize tier 1B
and tier 2 viruses, including the CAP228 autologous transmitted/
founder virus, consistent with the occlusion of these epitopes on
entry-competent envelope trimers (Table S3).
TheADCCactivityof theCAP228mAbswas initiallyassessedby
the granzyme B assay using a clade C gp120 from strain 1086. All
mAbs were re-expressed in an IgG1 backbone containing three
alanine mutations in the CH2 domain that improves FcgRIIIA
engagement (Ferrari et al., 2011;Shieldsetal., 2001). In this format,
all three CAP228 antibodies had ADCC activity comparable to the
RV144 vaccine antibodies CH58 and CH59 (Figures 4D and S4A).
The mAb A32 is specific for the inner domain of gp120, has a
well-defined ADCC activity, and was used as the positive control
(Ferrari et al., 2011; Moore et al., 1994), while Palivizumab (a
non-HIV respiratory syncytial virus [RSV]-specific mAb) was
used as the negative control. The specificity of the ADCC activity
was determined by introducing K169E or H173Y mutations into
the 1086 gp120. The K169E mutation substantially affected
ADCC by CAP228-16H/19F and almost completely abrogated
the activity ofCAP228-3DandCH58 (Figure 4D, cyan). In contrast,
the H173Y mutation only affected the ADCC activity of CH59,
consistent with previous studies (Liao et al., 2013). Control
antibodies A32 or Palivizumab remained unaffected by either
mutation.
The breadth of ADCCmediated by theCAP228mAbswas then
assessed against the autologous transmitted/founder virus, as
well as a multiclade panel of viruses (Figures 4E and S4B), using
an infectedcell assaywhere cell killing ismeasuredasa reduction
of the Luciferase signal provided by the infected cells (Pollara
et al., 2014). The CAP228 mAbs showed broader and more
potent reactivity compared to CH58 (Figure 4E, highlighted in
red), mediating high levels of ADCC against 6 of the 12 infected
cell targets including the CAP228 transmitted/founder virus (Fig-
ure 4D, labeled in gray). This difference appeared to trackwith the
immunotype at position 173 (Figure 4D, shaded green or purple).
RV144 mAb CH58 only showed high ADCC activity against
viruses with an H173 immunotype, mediating weak, sporadic
killing of cells infected with the Y173 immunotype, while CH59
was intolerant of the Y173 immunotype. The ADCC potency of
all five V2 antibodies also tracked well with changes at position
169, where 169R viruses displaying resistance to all mAbs, while
169T or 169I were resistant to the CAP228 mAbs, or CH58
respectively. For a few viruses, ADCC activity was more moder-
ate/weak and differed between the CAP228 mAb lineages. Both
CM244 and TV1.21 have longer, more glycosylated V1 loops
compared to the other viruses (32- and 37-amino acid loop
lengths and 6 glycans, respectively), potentially contributing to
resistance. Overall, these data are consistent with ADCC
directed to a V2 epitope and demonstrate the ability of CAP228
mAbs to recognize a broader range of viral immunotypes.
DISCUSSION
The V2 region of the HIV-1 envelope has become an increasingly
attractive target for vaccine immunogen design following theCell Reports 25, 3123–3135, December 11, 2018 3129
Figure 4. Increased V2 Coverage and Broader ADCC Activity Mediated by CAP228 Antibodies
(A) Buried surface area for V2 peptides residues 165–182 (x axis) from the CAP228-16H (purple) or CH58 (green) cocrystal structures, plotted as a percentage of
the total accessible surface area (y axis). Significant differences between the two structures are boxed in yellow, and hydrogen bonds (H) or salt bridges (S) are
labeled. The potential interaction between CAP228-16H and a sulfated tyrosine at position Y177 is indicated with the asterisk.
(B) Global frequency (y axis) of amino acids occurring at V2 positions 165–182 (x axis), from non-redundant sequences in the HIV-1 Los Alamos National
Laboratory (LANL) database, aligned with V2 residues in (A). Positively or negatively charged residues are colored blue or red, while the tyrosines recognized by
CAP228-16H, and the histidine required for CH58 are colored purple and green, respectively. Position 173 is boxed in yellow.
(legend continued on next page)
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demonstration that V2 peptide-binding antibodies correlated
with reduced risk of infection in the RV144 vaccine trial (Haynes
et al., 2012; Rerks-Ngarm et al., 2009). Recognition of these V2
antigens relies on key interactions with lysine residues at
positions 168, 169, and 171 through a mechanism thought to
be restricted to two light chain V genes. Here, we identify an
additional light chain V gene that uses an alternative mode of
recognition, allowing for broader reactivity with global strains.
The CAP228 mAbs, isolated from an HIV-1 subtype C-infected
individual, were shown to mediate ADCC against a larger panel
of infected cells compared to mAbs from RV144. Overall, these
data improve our understanding of the immunogenicity of V2
and suggest an increased ability to respond to RV144-like vac-
cines in populations where suitable alleles are more prevalent.
The isolation of antibodies from HIV-1-infected donors that
resemble those from vaccine recipients suggests that RV144
mAbs were elicited by envelope conformations that are naturally
expressed during HIV-1 infection. As such, studies of mAbs
isolated from donors such as CAP228 are highly relevant for un-
derstanding how the RV144 vaccine may have mediated its
protective effect. Screening of donor sera revealed that while an-
tibodies to V2 were commonly elicited during chronic HIV-1
infection, only 2 of 15 individuals showed a dominant binding
pattern similar to the RV144 mAbs CH58 and CH59. This sug-
gests that cross-reactive, linear peptide-associated, K169-
dependent V2 response may be less immunodominant in HIV
infection, and perhaps explains why these types of V2 mAbs
have not previously been isolated from infected donors. In keep-
ing with this, we found the frequency of V2 K169-specific B cells
in CAP228 to be extremely low, as less than 1 per 25,000 mem-
ory B cells were isolated by the differential sorting approach.
Transcripts from both CAP228 mAb lineages were detected
at 7 wpi, suggesting that they arose early, and possibly simulta-
neously, co-incident with the appearance of V2-binding anti-
bodies in CAP228 serum. All of the CAP228mAbs showed subtle
differences in V2 recognition compared to CH58, including being
considerably less dependent on residue K169, which may reflect
their need to adapt to an evolving viral antigen. Of the two line-
ages, CAP228-3D was most CH58-like in that it shared the
same IGLV6-57 light chain gene. However, transcripts from the
CAP228-3D lineage were found at very low frequency, with
detection of the heavy chain only at a single time point. In
contrast, the CAP228-16H/19F lineage heavy and light chain
transcripts were seen across all time points, peaking at 47weeks
(which coincided with high V2-binding titers) and appeared to be
the dominant response. Whether or not the unique heavy-light
chain pairing of the CAP228-16H/19F lineage conferred a selec-
tive advantage is still to be determined. Similarly, the isolation of
two lineages that used the same heavy chain as CH58 may(C) Neutralization activity of the CAP228 mAbs, or RV144 mAbs CH58 and CH59,
colored red, while those between 1 and 10 mg/mL are shown in orange, and tho
(D) Mapping the V2-directed ADCC activity by the granzyme B assay against HI
curve (y axis) for wild-type (blue), K169E (cyan), or H173Y (purple) mutant protei
(E) ADCC activity of the CAP228 mAbs against CEM.NKR-CCR5 cells infected w
report percentage activity versus antibody concentration as area under the curve
red; 200–400, in orange; 40–200, in yellow; and <40, in white. Relevant genotyp
immunotypes at residues 169 and 173. ThemAb A32with known ADCC activity w
while Palivizumab (a non-HIV antibody) was included as a negative control.indicate a genetic advantage for IGHV5-51 when accessing the
V2 site that warrants further study.
Antibodies able to bind V2 peptides were thought to be limited
to the two germline light chain genes IGLV3-10 and IGLV6-57
that contain a pre-configured EDmotif (Wiehe et al., 2014). Simi-
larly, mAbs isolated from V2-immunized rhesus macaques
almost always used the IGLV3-17 light chain gene (an ortholog
of human IGLV3-10) (Wiehe et al., 2014). This suggested a poten-
tial genetic restriction within the naive repertoire of B cells able to
respond appropriately to RV144-type vaccines. Our identifica-
tion of an additional light chain gene used by CAP228-16H/
19F, which can form productive K169-dependent V2 peptide
interactions, is therefore encouraging. Structural studies re-
vealed that this IGLV3-21 light chain uses a different CDRL2
arrangement to bind K169, which allowed us to define a DDxD
motif that serves as a surrogate for the ED motif. Generation of
an artificial antibody with an EDxD motif revealed equivalent
binding activity, indicating that this allele can accommodate
the traditional mode of binding, although the precise interactions
would need to be confirmed structurally. Two of the International
Immunogenetics Database (IMGT)-defined IGLV3-21 alleles
(*02 and *03) have this DDxD motif, while the third IGLV3-21*01
allele has a YDxD motif. Interestingly, germline sequencing of
IGLV3-21 fromdonor CAP228 revealed two alleles not previously
reported in the IMGT database (Lefranc, 2001), indicating the
importance of more inclusive online databases. Expression
and testing of the UCA with a YDxD motif (IGLV3-21*01m) sug-
gested that B cells carrying this allele were not engaged by the
infecting virus. Rather, this lineage derived from the IGLV3-
21*01mm allele, containing the DDxD motif. Reversion of
IGLV3-21*01mm allele to contain the *02 and *03 amino acid
changes showed no impact on binding to the autologous
CAP228 transmitted/founder V1V2, suggesting that all DDxD-
motif-containing alleles are equally functional in binding V2
antigens. The discovery of two undocumented alleles in one in-
dividual, in addition to the three previously reported alleles within
the IGLV3-21 light chain gene, suggests that significant variation
exists within the African genome as previously demonstrated for
the heavy chain variable region (Scheepers et al., 2015). Since
the IGLV3-21*01mm allele contains the DDxD motif, this in-
creases the repertoire of light chain alleles able to bind V2 and
could increase V2 antibody response rates and titers to
RV144-like vaccines.
In addition to expanding the B cell repertoire able to recognize
K169, the IGLV3-21 gene used by CAP228-16H also forms pro-
ductive interactions with Y173 in V2, potentially conferring
increased recognition of heterologous strains. Consistent with
this, CH58 showed strong ADCC against viruses with the H173
immunotype, while CAP228 antibodies recognized viruses thatin the TZM-bl assay against six tier 1A HIV-1 viruses. IC50 titers%1 mg/mL were
se between 10 and 50 mg/mL are shown in yellow.
V-1 1086 gp120-coated target cells. Measurements represent area under the
ns.
ith a multi-clade panel of 12 HIV-1 strains, compared to CH58 and CH59. Data
, above 15% background, and are displayed as a heatmap with >400 shown in
ic information for each envelope strain is also shown, grouped according to
as included as a positive control and showed reactivity against all infected cells,
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contained both the H173 as well as the more globally prevalent
Y173 immunotype. These data suggest that the ability to accom-
modate Y173, in part due to the use of this newly implicated
IGLV3-21 light chain, may have resulted in broader ADCC activ-
ity, and these results are consistent with the relatively high ADCC
activity previously measured in CAP228 plasma (Richardson
et al., 2018). Antibodies fromRV144, such asCH58, were elicited
by a vaccine strain with an H173 immunotype that is relevant to
clade AE (which predominates in Thailand), while CAP228 anti-
bodies were elicited by a virus with a Y173 immunotype. While
this likely contributed to selection of IGLV3-21 used by the
CAP228-16H/19F mAbs, the CAP228-3D mAb (which uses an
ED-motif-containing light chain) was also elicited by the same
Y173-containing viruses. CAP228-3D interactions with Y173,
like CH58 interactions with H173, are exclusively mediated by
the heavy chain CDRH3. Another RV144 mAb, CH59, binds to
a different H173-dependent conformation of V2 but failed to
bind the peptides or V1V2 scaffolded proteins used in this study
with the more globally prevalent Y173 immunotype. The specific
immunotype presented at position 173 might therefore form an
important antigenic determinant of V2 immunogens. Similarly,
the ability to recognize a sulfated Y177 residue, which is less
frequently observed on recombinant immunogens when
compared with virus associated V1V2 (Cimbro et al., 2014),
may improve V2 mAb antiviral activities. These data highlight
key differences between CAP228 antibodies elicited through
HIV-1 infection, which were more cross-reactive with circulating
viral strains than mAbs elicited by vaccination, and suggest that
antigens more representative of the diversity within V2 could
elicit broader and more potent antiviral responses than RV144.
ADCC activity was identified as a correlate of reduced risk of
HIV-1 infection, and mAbs isolated from RV144 also showed
strong ADCC activity (Bonsignori et al., 2012; Haynes et al.,
2012; Pollara et al., 2014). Here, we show that the ADCC activity
of all tested V2 mAbs was largely restricted to cells infected with
viruses that harbored a K169 residue in V2, although the IGHV5-
51/IGLV3-21 pairing appeared to be more tolerant of variation at
this position. This further supports the genetic signature analysis
showing that breakthrough infections in RV144 were under-rep-
resented for K169 (Rolland et al., 2012). While this has been
attributed to a genetic sieve effect, i.e., that K169-containing
viruses were selectively prevented from establishing infection,
mutations away from K169 may also have arisen post-acquisi-
tion as a result of antibody selection pressure, possibly through
ADCC (Rolland et al., 2012). Increasingly, the Fc effector func-
tions of antibodies have been shown to play an important role
in antiviral efficacy (Horwitz et al., 2017), but direct evidence
for viral selection is limited mainly because of the difficulty of
analyzing the role of ADCC separately from that of antibody
neutralizing activities.
The RV144 trial conducted in Thailand is the only HIV-1 vac-
cine to show some level of efficacy, and follow-up studies of
this approach are being actively pursued. In the HVTN 097 phase
I trial, which tested the same vaccines used in RV144, antibody
responses to V2were found to be higher in Africans compared to
Thais (Gray et al., 2014). A follow-up study called HVTN 100, that
used clade C versions of these vaccine immunogens, passed all
pre-set go/no-go criteria, which included V2 antibody response3132 Cell Reports 25, 3123–3135, December 11, 2018rates (Bekker et al., 2018). These data suggest that V2 antibodies
will be readily elicited in HVTN 702, the current efficacy study that
is enrolling 5,400 high-risk men and women in South Africa. It
remains to be seen whether modifications to the regimen, which
includes new HIV-1 clade C components, additional protein
boosting, and a different adjuvant, results in higher levels of effi-
cacy compared to RV144. Importantly, this trial will confirm
whether or not V2 antibodies with ADCC activity are a correlate
of reduced risk of HIV-1 infection. Our data, showing that South
Africans can respond to V2 antigens using additional genetic
determinants, expands the opportunities for responding favor-
ably to RV144-like vaccines, but confirmation of this awaits
isolation and characterization of mAbs from participants in the
HVTN 702 trial.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
CAPRISA cohort
The CAPRISA 002 Acute Infection study, established in 2004, followed HIV-1 subtype C infected adult women (> 18 years) attending
urban and rural clinics from seroconversion through to the initiation of antiretroviral therapy in Durban and Vulindlela, South Africa
(van Loggerenberg et al., 2008). It was reviewed and approved by the research ethics committees of the University of KwaZulu-Natal
(E013/04), the University of Cape Town (025/2004), and the University of the Witwatersrand (MM040202). All participants
provided written informed consent for study participation. CAP228 enrolled into this study following infection with a HIV-1
subtype C virus in March 2005. She was initially identified as a virological controller, having a CD4 count of > 350 cells/mL and a viral
load of < 2000 copies/mL on at least two consecutive measurements after 6 months of infection (Gray et al., 2007). However, anti-
retroviral therapy was started in June 2012 following a peak viral load of 228,207 RNA copies/mL at 370 wpi.
METHOD DETAILS
Cell sorting
Single-cell sorting of antigen-specific B cells was performed as previously described (Morris et al., 2011; Wu et al., 2010) with the
following modifications. Biotinylated CAP45 cyclic peptides comprising gp120 residues 157 – 196 (Genscript) were labeled with
either Brilliant Violet 421 (BV421, Biolegend), or AlexaFlour 647 (AF647, Life Technologies), conjugated to streptavidin. CAP228
PBMCs were stained with a variety of cell surface markers (BD Biosciences) as well as live/dead stain (Invitrogen), and antigen-
specific memory B cells were sorted as CD3-, CD14-, CD16-, CD19+, IgD- and CAP45 peptide K169+ E169- into 96-well PCR plates
containing lysis buffer, using a BD FACS Aria II (BD Biosciences). In a second sort, the CAP228 autologous transmitted/founder V1V2
domain was scaffolded onto PDB ID: 1FD6 (McLellan et al., 2011), and labeled with BV421 as an additional positive bait. Data were
analyzed using FlowJo (Tree Star).
Single cell PCR amplification of heavy and light chain variable genes
The genes encoding IGHV and IGLV chains were amplified from sorted cells by RT and nested PCR using a combination of two
published methods. Reverse transcription was performed using Superscript III reverse transcriptase (Invitrogen) and random hex-
amer primers. Following cDNA synthesis VH, Vk, and Vl antibody genes were amplified as previously described (Doria-Rose
et al., 2015; Liao et al., 2009). Primer sequences are listed in Tables S4 and S5.
Protein expression and purification
Sorted mAbs were first amplified as linear cassettes used directly to transfect HEK293T cells (obtained from the NIH AIDS Research
and Reference Reagent Program, Division of AIDS, NIAID, NIH) grown at 37C, 10% CO2. The resulting supernatants were tested in
ELISA for IgG concentration and antigen reactivity as previously described (Gray et al., 2011b). Following confirmation of expression
and binding, the mAbs were sub-cloned and expressed in a wild-type IgG1 backbone, as well as an IgG1 backbone with the S298A,
E333A, and K334Amutations in CH2 (3A variant) for ADCC experiments (Shields et al., 2001). Monoclonal antibodies were produced
by co-transfection of heavy and light chain encoding plasmids into HEK293F cells (Invitrogen) grown at 37C, 5%CO2, 70%humidity,
and 125 rpm. Cultures were harvested after seven days by centrifugation at 3000 xG, and supernatants were filtered through 0.22 mm
before purification by protein A chromatography.
V1V2 scaffolded miniproteins were expressed in HEK293S cells grown at 37C, 5% CO2, 70% humidity, 125 rpm (ATCC
CRL-3022, N-acetylglucosaminyltransferase I deleted), to yield a uniform low-mannose glycan content. Cultures were harvested
after seven days as above and purified by sequential Ni-NTA and size exclusion (SEC) chromatography.
ELISA
Biotinylated cyclic V2 peptides from CAP45 (JPT peptides) were captured onto Streptavidin coated ELISA plates at a concentration
of 2 ng/mL at 37C for one hour. Plates were blocked with 5%milk and washed in PBS (0.05% tween20) before being probed at 37C
for one hour with serial dilutions of sample antibodies, starting at 10 mg/mL. After a subsequent washing step, HRP-conjugated
goat anti-human IgG (H+L) polyclonal antibodies (Sigma-Aldrich) diluted to 1:5,000 were added to the plate and incubated for
one hour at 37C. Bound antibodies were detected using TMB substrate, and the reactions were stopped by the addition of 1 M
H2SO4. Absorbance was read at 450 nm.
The CAP228 V1V2-1FD6 scaffolds were coated at 5 mg/mL onto high protein-binding microplates overnight at 4C. Plates were
blocked and washed as above, and probed with plasma serially diluted from 1:100, or mAbs from 10 mg/mL, for one hour ate3 Cell Reports 25, 3123–3135.e1–e6, December 11, 2018
37C. Followingwashing, bound antibodies were detectedwith HRP-conjugated anti-human antibodies (Sigma-Aldrich) at a concen-
tration of 1:1000 for one hour at 37C, followed by TMB substrate stopped with 1 M H2S04. Absorbance was read at 450 nm.
Neutralization assay
Single round of replication Env-pseudotyped viruses were prepared using the pSG3DEnv plasmid in HEK293T cells, and titered to
infect TZM-bl target cells as described previously (Montefiori, 2009). Cell lines and virus plasmids were obtained from the NIH AIDS
Research and Reference Reagent Program, Division of AIDS, NIAID, NIH. Neutralization was calculated as a reduction in
luminescence units compared with control wells, and reported as 50% inhibitory concentration (IC50).
Infectious molecular clones (IMC)
The HIV-1 reporter virus used was a replication-competent infectious molecular clone (IMC) designed to encode the 1086.B2
(subtype C; GenBank No. FJ444395), CM235.2 (subtype A/E; GenBank No. AF259954.1), CM244 (subtype A/E; GenBank
No. KC822429), CAP228.2.00.51J (subtype C; GenBank No. EF203968), MW965.26 (subtype C; GenBank No.U08455), DU151.2
(subtype C; GenBank No. DQ411851), TV1.21 (subtype C; GenBank No. HM215437), C1080.3 (subtype AE; GenBank
No. JN944660), WITO.c (subtype B; GenBank No. JN944948), CH040.c (subtype B; GenBank No. JN944939), Q23.17 (subtype A;
GenBank No. AF004885) and CH0505.w4.24 (subtype C; GenBank No. KC247577) env genes in cis within an isogenic backbone
that also expresses the Renilla luciferase reporter gene, and preserves all viral open reading frames (Edmonds et al., 2010; Li
et al., 2005). The subtype AE Env-IMC-LucR virus used was the NL-LucR.T2A-AE.CM235-ecto (IMCCM235) (plasmid provided by
Dr. Jerome Kim, US Military HIV Research Program). All the other IMCs were built using the NL-LucR.T2A-ENV.ecto backbone as
originally described (Adachi et al., 1986). Reporter virus stocks were generated by transfection of HEK293T cells with proviral
IMC plasmid DNA, and titered in TZM-bl cells for quality control.
Coated ADCC assay
ADCC activity was detected by the previously described ADCC-GranToxiLux (GTL) assay using antigen-coated cells (Pollara et al.,
2011). Whole PBMCs from a healthy donor were used as effector cells for which the FcgRIIIa receptor was genotyped as being ho-
mozygous for valine at position 158 by the TaqMan SNP genotyping assay (rs396991) (Applied Biosystems) to ensure high levels of
lysis. Target CEM-NKR.CCR5 cells were coated with wild-type 1086 gp120 and K169E or H173Y mutants at optimal concentrations
determined by titration. The monoclonal antibody A32 was used as a positive control and Palivizumab (MedImmune, LLC) was used
as the negative control. The results were analyzed in FlowJo (FlowJo LLC) and are shown as%Granzyme B (GzB) activity, defined as
the percentage of cells positive for proteolytically active GzB out of the total viable target cell population. The final results exclude the
subtracted background value determined by the % GzB activity observed in wells containing effector and target cell populations in
the absence of IgG.
Infected cell ADCC assay
The infected cell assay was used to measure ADCC activity as previously described (Pollara et al., 2014). We utilized a modified
version of our previously published ADCC luciferase procedure (Karasavvas et al., 2012; Liao et al., 2013). Briefly, a laboratory-
derived clone of the CEM.NKRCCR5 cell line (NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH from Dr. Alexandra Trkola)
was used as targets for ADCC luciferase assays after infection with the HIV-1 IMCs listed above (Trkola et al., 1999). The target
cell line was infected with IMC using titered stock that generated more than 20% infected target cells after 48-72 hours of infection.
The target cells were incubated with 5-fold serially diluted mAbs starting at 50 mg/mL. Cryopreserved peripheral blood mononuclear
cells (PBMC) obtained from an HIV-1 seronegative donor with the geographically common 158F/V Fcg receptor IIIa phenotype were
used as source of effector cells. After thawing, the cryopreserved PBMCswere rested overnight and used at an effector to target ratio
of 30:1. The effector cells, target cells, and Ab dilutions were plated in opaque 96-well half area plates and incubated for 6 hours at
37C in 5%CO2. The final readout was the luminescence intensity (in relative light units) generated by the presence of residual intact
target cells, that have not been lysed by the effector population in the presence of any ADCC-mediating mAb. The percentage of
killing was calculated using the formula:
% Killing=
ðRLU of Target and Effector wellÞ  ðRLU of test wellÞ
RLU of Target and Effector well
3 100
In this analysis, the RLU of the target plus effector wells represents spontaneous lysis in absence of any source of antibody. The
RSV-specific mAb Palivizumab was used as a negative control and A32 as the positive control. Data are represented as the area
under the curve of percentage specific killing over the serially diluted antibodies, calculated above a 15% background cutoff.
Autoreactivity assays
All isolated mAbs were screened for autoreactivity using the ZEUS AtheNA Multi-Lyte ANA-II Plus Test System (Zeus Scientific),
which semiquantitatively detects IgG antibodies to 8 separate analytes: SSA, SSB, Sm, RNP, Scl-70, Jo-1, Centromere B, and
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Next generation sequencing using the Illumina MiSeq platform
Total RNA was extracted from cryopreserved PBMC using the QIAGEN AllPrep DNA/RNA mini kit as per the manufacturer’s spec-
ifications, and reverse transcription was carried out using Random Hexamers and Superscript III RT enzyme (Thermo Fisher
Scientific). Primers specific to the heavy and light chains (Tables S4 and S5) of CAP228-16H and CAP228-3D were based on
previously published primers (DeKosky et al., 2013; Doria-Rose et al., 2014; Liao et al., 2009), such that forward primers binding
in the leader sequence or V-region (VH5int, VL3-21, and VL6-57) and reverse primers in the constant region (IGHGR, 3CL) weremodi-
fied for use on the Illumina MiSeq Platform. Samples from each time point were amplified seven times for both the heavy and light
chains to ensure adequate coverage and minimize PCR bias. A plasmid control containing the CH58 antibody sequence was also
amplified. PCR conditions were as previously described (Scheepers et al., 2015) except that annealing temperatures were 58C
and 55C for heavy and light chains respectively. Nextera XT Indexing tags were added to the pooled MiSeq amplicon libraries.
All products were checked on an Agilent bioanalyser and cleaned-up using 0.75x Ampure Beads (Beckman-Coulter), using the man-
ufacturer’s protocol. A final concentration of 12 pM denatured DNA library with 15% PhiX control was run onto the Illumina MiSeq,
using the MiSeq reagent kit (version 3) with 2 3 300 paired-end reads.
Next generation sequencing data processing and analysis
Paired-end MiSeq reads were merged into full-length reads for each time point using PEAR (Zhang et al., 2014). Paired sequences
were then de-replicated using USEARCH (Edgar, 2010) resulting in unique reads. The SONAR bioinformatics pipeline (Schramm
et al., 2016) was used to identify clonally related reads to CAP228-16H and CAP228-3D. In brief, germline V and J genes were
assigned, the CDR3 regions were identified, and identity to CAP228-16H / CAP228-3D for each of the reads was calculated. Iden-
tity-divergence plots, created through SONAR, were used to visualize the level of germline divergence from the relevant germline
genes and the percentage identity to each antibody for all unique reads. Clonally related sequences were selected based on germline
gene usage and CDR3 identityR 80% to the mAbs. To account for sequencing and/or PCR error, all singletons were removed and
the remaining sequences were clustered at 99% identity using USEARCH, then one representative was selected from clusters with
three or more transcripts for downstream analyses. Best fit models for amino acid maximum likelihood phylogenetic trees were
calculated and constructed using MEGA6 and PhyML 3.0 (Guindon et al., 2010; Tamura et al., 2013). The trees were displayed in
Dendroscope (Huson and Scornavacca, 2012).
Germline gene amplification and cloning
Primers specific to the IGLV3-21 germline gene were designed (Tables S4 and S5) to amplify all alleles from stored genomic DNA
using the HotStarTaq Plus DNA polymerase (QIAGEN), as per manufacture recommendations (with an annealing temperature of
56C). Amplicons were cloned using the TOPO TACloning kit (Thermo Fischer Scientific), then colonies were screened by PCR using
TOPO TA kit provided primers, and assessed by Sanger sequencing.
X-ray protein crystallography
The CAP228-16H variable domain was subcloned into an IgG1 expression construct containing a human rhinovirus (HRV) 3C pro-
tease cleavage site between the antigen binding (Fab) and crystallizable (Fc) antibody fragments. Expressed full length antibody
was digested with HRV 3C (Novagen), and the Fab fragment was purified by negative selection with protein A, before being
complexed with V2 peptide (residues 164 – 182) at two-fold molar excess, and further purified by size exclusion chromatography.
Fab-peptide complexes were flash frozen at 13.1 mg/mL. The initial crystallization hit (20% polyethylene glycol 8000 (PEG8000),
200 mM sodium chloride, 100 mM Na2PO4/C6H8O7 pH4.2) was identified from a manual 384 well sitting drop screen that included
Wizard Precipitant Synergy and Wizard Classic 1-4 screen reagents (Rigaku) mixed at 1:1 with protein to a total of 400 nL – 600 nL
per drop. Crystal growth conditions were further optimized in 15-well hanging-drop vapor diffusion plates (QIAGEN) by successive
additive screens to include 160 mM ammonium sulfate and 8% 2-methyl-2,4-pentanediol (MPD). Crystals grew to approximately
0.3 mm in diameter and were further dehydrated and cryoprotected in a drop containing 25% PEG8000, 250 mM NaCl, 200 mM
ammonium sulfate, 100 mM Na2PO4/C6H8O7 (pH4.2), and 25% MPD before flash freezing. The final product was manually thawed
briefly ‘on-loop’ to encourage crystal repacking, and then diffracted to 2.6A˚ at the Brazilian Synchrotron Light Laboratory (LNLS)
MX-2 beamline using a 1.00A˚ wavelength at 100K. The data were processed using HKL2000, solved with Phaser using PDB acces-
sion no. 4HQQ as the search model, and refined with the PHENIX suite. Models were built in Wincoot using 5% of reflections as an
Rfree test set, and including hydrogen atoms to help avoid clashes. All protein structure images weremadewith the PyMOLMolecular
Graphics System, Version 1.3r1edu (Schrodinger LLC). The structure has been deposited in the PDB with accession code 6FY0.
DATA AND SOFTWARE AVAILABILITY
All flow cytometry data were analyzed using FlowJo (Tree Star). MiSeq reads were merged with PEAR (Zhang et al., 2014), de-repli-
cated and clustered with USEARCH (Edgar, 2010), and processed with the SONAR bioinformatics pipeline (Schramm et al., 2016).
Phylogenetic associations were made using MEGA (Tamura et al., 2013) and PhyML (Guindon et al., 2010). The isolated antibodye5 Cell Reports 25, 3123–3135.e1–e6, December 11, 2018
variable domain gene sequences were deposited in GenBank (Accession codes MK119167 to MK119171), and all antibody lineage
sequencing data was deposited in the Sequence Read Archive (PRJNA498753 Accession codes: SAMN10334092 to
SAMN10334110). Structural data was processed with HKL2000, and subsequently solved and refined with the PHENIX core suite
andWincoot. Structure factors were deposited in the Protein Databank (PDB 6FY0). Graphics were generated using PyMOL (Schro-
dinger LLC).Cell Reports 25, 3123–3135.e1–e6, December 11, 2018 e6
